Life expectancy in patients with multiple myeloma is increasing because of the availability of
an increasing number of novel agents with various mechanisms of action against the …

Abstract Purpose of Review We discuss current topics on the definition of plasma cell
leukemia and the distinction between plasma cell leukemia and multiple myeloma …

Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after
progress in the last decades. PCL deserves a prompt identification to start the most effective …

PURPOSE Primary plasma cell leukemia (PCL) is the most aggressive monoclonal
gammopathy. It was formerly characterized by≥ 20% circulating plasma cells (CTCs) until …

Here, we investigated for the first time the frequency and number of circulating tumor plasma
cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and …

The presence of circulating plasma cells in patients with multiple myeloma is considered a
marker for highly proliferative disease. In the study herein, the impact of circulating plasma …

The current definition of plasma cell leukemia (PCL)—≥ 20% circulating plasma cells
(CPCs) on peripheral smear and plasma cell count≥ 2× 109/L—may be too stringent. We …

Multiparameter flow cytometry (MFC) has become standard in the management of patients
with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of …

PURPOSE Primary plasma cell leukemia (pPCL) is an aggressive subtype of multiple
myeloma, which is distinguished from newly diagnosed multiple myeloma (NDMM) on the …

We have developed an automated assay to enumerate and characterize circulating multiple
myeloma cells (CMMC) from peripheral blood of patients with plasma cell disorders. CMMC …